Does Humana Cover Weight Loss Treatment in Hawaii? A 2026 Guide

Last updated: July 17, 2026

Key facts for Hawaii Humana members: Humana offers only Medicare Advantage (MA) plans in Hawaii as of 2024 — no commercial individual or group plans. PBM: Humana Pharmacy Solutions (HPS). Governing authority: CMS 42 CFR Part 422 (federal — Hawaii’s commercial parity law § 431M-1 and the Hawaii Prepaid Health Care Act § 393 do not apply to MA plans). Breaking: Medicare GLP-1 Bridge launched July 1, 2026 — eligible Humana MAPD members in Hawaii may access Wegovy, Zepbound, or Foundayo at $50/month via CMS, outside the standard HPS Part D formulary. Dual-eligible (D-SNP) members: contact Hawaii Med-QUEST at 1-800-316-8005. EPCS: entirely inapplicable to weight loss medications under HRS § 329-38.5 (Schedule II only — no weight loss drug falls in Schedule II). For coverage verification: Humana 1-800-448-6262 | HPS 1-800-379-0092 | CMS 1-800-633-4227.

If you have a Humana Medicare Advantage plan in Hawaii and are exploring weight loss treatment, 2026 marks a turning point. A major new federal program — the Medicare GLP-1 Bridge — may now give eligible Humana MAPD members access to leading weight loss medications at a fraction of their typical cost, even if those drugs are not on the standard HPS Part D formulary. This guide walks through what is available, how coverage works, what to expect with prior authorization, and how Hawaii’s state laws apply (or don’t) to your Humana MA plan.

See If You May Qualify for Weight Loss Treatment →

Humana in Hawaii: Medicare Advantage Only

Humana exited the commercial individual and group health insurance market in most states, including Hawaii, effective January 1, 2024. This means that if you have a Humana plan in Hawaii today, it is a Medicare Advantage (MA) or Medicare Advantage Prescription Drug (MAPD) plan. Common Humana MA plan types available in Hawaii have included:

• Humana Gold Plus HMO — network-based, lower premiums
• HumanaChoice PPO — out-of-network flexibility
• Humana Honor HMO-POS — point-of-service flexibility
• Humana R/H PPO — regional/national PPO coverage

Prescription drug coverage under these plans runs through Humana Pharmacy Solutions (HPS), Humana’s own pharmacy benefit manager. Because these are Medicare Advantage plans, all coverage decisions — including parity requirements, formulary appeals, and prior authorization timelines — are governed by CMS 42 CFR Part 422, not by Hawaii state commercial insurance statutes.

Medicare GLP-1 Bridge: The Most Important 2026 Update for Hawaii Humana Members

Effective July 1, 2026, CMS launched the Medicare GLP-1 Bridge Program, which provides eligible Medicare Advantage Prescription Drug (MAPD) members access to certain GLP-1 weight loss medications at a flat cost of $50 per month per drug. This benefit applies outside the standard HPS Part D formulary — meaning it may be available even if the drug is not listed on your plan’s regular drug formulary.

The three medications currently covered under the Medicare GLP-1 Bridge are:

• Wegovy (semaglutide, weekly injection) — indicated for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity
• Zepbound (tirzepatide, weekly injection) — indicated for chronic weight management; dual GIP/GLP-1 receptor agonist
• Foundayo (tirzepatide) — newly approved oral formulation, also included in the bridge program as of its June 2026 market entry

Who is eligible? Eligibility under the bridge program generally requires:

1. Active enrollment in a Medicare Advantage Prescription Drug (MAPD) plan (such as a Humana Gold Plus HMO or HumanaChoice PPO)
2. A qualifying diagnosis: obesity (BMI ≥30) or overweight (BMI ≥27) with at least one comorbidity such as hypertension, type 2 diabetes, hyperlipidemia, or obstructive sleep apnea
3. A prescription from an enrolled Medicare provider
4. No active cardiovascular contraindications for GLP-1 therapy (your prescribing provider will assess this)

To access the bridge benefit, contact Humana at 1-800-448-6262 or HPS at 1-800-379-0092 and ask specifically about the Medicare GLP-1 Bridge benefit. This benefit operates outside the standard HPS formulary structure — do not rely solely on checking the online formulary, which may show these drugs as non-covered under traditional Part D rules.

Important distinction: Medicare Part D historically excluded drugs approved solely for weight loss (42 U.S.C. § 1395w-102(e)(2)(A)). The Medicare GLP-1 Bridge is a CMS program established effective July 1, 2026 that operates alongside Part D, not as a standard Part D formulary tier. It applies to MAPD plans only — it does not apply to standalone Part D plans or to commercial (non-Medicare) Humana plans.

HPS Part D Weight Loss Formulary

For weight loss medications beyond the GLP-1 Bridge, the standard HPS Part D formulary typically applies. Note that traditional Part D coverage rules for weight loss drugs remain restrictive outside the bridge program. The table below reflects the general HPS formulary structure as of 2026; verify current coverage for your specific plan at humana.com/pharmacy or by calling HPS at 1-800-379-0092.

Always verify your specific plan’s formulary at humana.com/pharmacy or call HPS at 1-800-379-0092. Formularies may change mid-year; the table above reflects general HPS Part D parameters as of July 2026.

Prior Authorization Process for Weight Loss Medications

If you are pursuing coverage under the Medicare GLP-1 Bridge or standard HPS formulary, prior authorization (PA) will likely be required. Here is what to expect:

Standard CMS PA Timelines (42 CFR Part 422)

• Standard PA decision: within 72 hours of receiving the request
• Expedited PA decision (urgent/serious medical situation): within 24 hours
• If Humana/HPS does not respond within these federal timeframes, you have grounds for an expedited appeal

What Your Provider Will Need to Submit

• Documented BMI ≥30 (or ≥27 with qualifying comorbidity such as hypertension, type 2 diabetes, hyperlipidemia, sleep apnea, or cardiovascular disease)
• Evidence of prior lifestyle intervention (diet counseling, exercise program — typically 3–6 months documented)
• Diagnosis codes (E66.x for obesity; E11.x for type 2 diabetes if applicable)
• Attestation that contraindications to GLP-1 therapy (e.g., medullary thyroid carcinoma history, pancreatitis history) have been evaluated
• For Foundayo: documentation of oral suitability vs. injection alternatives

How to Submit PA

• Providers submit PA requests through Availity at availity.com or directly through humana.com/providers
• Members may contact HPS at 1-800-379-0092 or Humana member services at 1-800-448-6262
• PA for the Medicare GLP-1 Bridge specifically: ask about the GLP-1 Bridge supplemental benefit — this may route through a different workflow than standard Part D PA

CMS Appeals Process (42 CFR Part 422)

If your PA request is denied, you have the right to appeal under federal MA regulations:

1. Redetermination — request from Humana/HPS within 60 days of denial
2. Reconsideration by Independent Review Entity (IRE) — Humana escalates to CMS-contracted IRE
3. ALJ Hearing — Administrative Law Judge (if amount in controversy ≥ $180 in 2026)
4. Medicare Appeals Council (MAC)
5. Federal District Court (if amount in controversy ≥ $1,870 in 2026)

For help navigating appeals: contact Hawaii’s State Health Insurance Assistance Program (SHIP) at 1-888-875-9229 (free, unbiased Medicare counseling).

EPCS (Electronic Prescribing for Controlled Substances) — Entirely Inapplicable

Hawaii’s Electronic Prescribing for Controlled Substances law (HRS § 329-38.5) requires electronic prescriptions for Schedule II controlled substances only. Not a single weight loss medication falls in Schedule II, so EPCS is entirely inapplicable to weight loss treatment in Hawaii:

Note: West Virginia’s EPCS statute (W. Va. Code § 60A-4-403a) covers ALL controlled substances including Schedule IV, so phentermine/Qsymia trigger EPCS in WV. Hawaii’s law is narrower — Schedule II only. This distinction matters for providers prescribing across state lines or operating in multiple states.

Hawaii State Insurance Laws: Do They Apply to Your Humana MA Plan?

Hawaii Mental Health Parity Law (§ 431M-1) — Does Not Apply

Hawaii’s mental health and substance use disorder parity law (Haw. Rev. Stat. § 431M-1 et seq.) governs commercial health insurance plans issued in Hawaii. It applies to commercial insurers and employer-sponsored group health plans. Because Humana’s Hawaii plans are Medicare Advantage plans regulated by CMS under 42 U.S.C. § 1395w-21 et seq., state commercial parity statutes do not apply. Your parity protections come from federal law — MHPAEA as implemented through CMS regulations for MA plans under 42 CFR Part 422.

Additionally, § 431M-1 covers mental health and substance use disorder benefits — it does not govern weight loss medication coverage regardless of plan type.

Hawaii Prepaid Health Care Act (§ 393) — Does Not Apply

The Hawaii Prepaid Health Care Act (HRS § 393) is Hawaii’s unique employer mandate requiring most Hawaii employers to provide health insurance to employees working 20+ hours per week. It applies to commercial employer-sponsored health plans. It does not apply to Medicare Advantage plans. Your Humana MA plan is governed entirely by CMS federal regulations.

ACA Essential Health Benefits — Limited Application to Medicare

The ACA’s Essential Health Benefits (EHB) framework (42 U.S.C. § 18022) primarily applies to individual and small group health plans sold through the marketplace. While Medicare Advantage plans must cover all services that traditional Medicare (Parts A and B) covers, weight loss drugs have historically been excluded from traditional Medicare Part D formularies under 42 U.S.C. § 1395w-102(e)(2)(A). The Medicare GLP-1 Bridge program (effective July 1, 2026) operates as a supplemental CMS benefit that extends beyond the traditional Part D exclusion for eligible members.

Governing Authority: CMS 42 CFR Part 422

All coverage decisions, network adequacy requirements, prior authorization timelines, and parity protections for your Humana Medicare Advantage plan in Hawaii are governed by CMS 42 CFR Part 422 and related federal MA regulations. Key protections include:

• PA timeline requirements: 72-hour standard, 24-hour expedited (§ 422.568)
• Non-interference with coverage decisions: MA plans may not implement utilization management that is more restrictive than traditional Medicare without actuarial justification
• Annual formulary change notice: HPS must notify members 60 days before removing a drug from the formulary mid-year
• Protected appeal rights: five-level CMS appeal chain (Redetermination → IRE → ALJ → MAC → Federal Court)
• Non-discrimination: MA plans may not discriminate against beneficiaries based on health status, mental health conditions, or chronic conditions (42 CFR § 422.110)

For complaints about Humana’s compliance with CMS MA regulations, contact CMS at 1-800-633-4227 or file a complaint at Medicare.gov. The Hawaii Insurance Division (1-808-586-2790) handles commercial insurance complaints but does not have jurisdiction over Medicare Advantage plans.

Weight Loss Conditions That May Qualify for Coverage

Under the Medicare GLP-1 Bridge and standard HPS medical benefit, weight loss treatment may be covered for the following qualifying conditions. Coverage is generally available when these conditions are clinically documented:

• Obesity (BMI ≥30) — primary qualifying diagnosis for GLP-1 medications; ICD-10 E66.01/E66.09
• Overweight with comorbidity (BMI ≥27) — qualifying comorbidities include: hypertension (I10), type 2 diabetes (E11.x), hyperlipidemia (E78.x), obstructive sleep apnea (G47.33), cardiovascular disease (I25.x)
• Metabolic syndrome — combination of central obesity, elevated triglycerides, low HDL, hypertension, and elevated fasting glucose
• Pre-diabetes with obesity — weight loss may reduce progression to type 2 diabetes; ICD-10 R73.09
• PCOS with obesity — polycystic ovary syndrome comorbid with overweight/obesity; ICD-10 E28.2

Your prescribing provider will document the appropriate diagnosis codes and clinical rationale when submitting the PA request to HPS or under the GLP-1 Bridge program.

Behavioral and Lifestyle Components of Weight Loss Coverage

In addition to prescription medications, your Humana MA plan may cover several behavioral and lifestyle weight loss services under the Medicare benefit:

• Intensive Behavioral Therapy (IBT) for Obesity: Medicare covers IBT for obesity in primary care settings — up to 22 high-intensity visits in the first year for members with BMI ≥30 (covered under Medicare Part B, not Part D)
• Medical nutrition therapy: covered by Medicare Part B for certain conditions (diabetes, kidney disease); ask your provider about applicability
• Telehealth weight loss visits: Humana MAPD plans may cover telehealth visits with licensed providers for obesity management — check your Summary of Benefits for telehealth cost-sharing
• Behavioral health support: co-occurring conditions such as binge eating disorder or depression comorbid with obesity may be covered under behavioral health benefits (CMS 42 CFR Part 422 parity applies)

Dual-Eligible Members: Medicaid and Medicare Coordination

If you are enrolled in both Humana Medicare Advantage and Hawaii Medicaid (Med-QUEST), you may have additional coverage pathways for weight loss treatment:

• Humana’s D-SNP (Dual Special Needs Plan) members in Hawaii have coordinated benefits between Medicare and Med-QUEST
• Some weight loss medications not covered under Part D may be available through Hawaii Medicaid’s fee-for-service or MCO formularies — verify with Med-QUEST
• Contact Hawaii Med-QUEST at 1-800-316-8005 to understand how your Medicaid benefits coordinate with your Humana MAPD coverage
• For the Medicare GLP-1 Bridge, the $50/month bridge co-pay may be further reduced or waived for full dual-eligible (QMB) members — ask Humana at 1-800-448-6262 about QMB protections

How Klarity Health Can Help

Klarity Health is an online telehealth platform with 2,000+ licensed providers across Hawaii and nationwide. Klarity providers may be able to:

• Evaluate you for obesity or overweight with qualifying comorbidities
• Prescribe GLP-1 medications (Wegovy, Zepbound, Foundayo) and other evidence-based weight loss treatments
• Submit prior authorization requests to Humana/HPS on your behalf, including for the Medicare GLP-1 Bridge program
• Provide ongoing monitoring and medication management via telehealth visits

Coverage may vary by plan. Always verify your Humana MAPD benefits before booking.

Check If You May Qualify for Weight Loss Treatment →

How to Verify Your Humana Hawaii Weight Loss Coverage: Step-by-Step

1. Call Humana member services: 1-800-448-6262 — ask specifically about the Medicare GLP-1 Bridge benefit and your plan’s weight loss medication coverage
2. Contact HPS pharmacy: 1-800-379-0092 — verify formulary tier, PA requirements, and bridge program eligibility for Wegovy, Zepbound, or Foundayo
3. Check your Summary of Benefits: Available at humana.com/pharmacy — look for “weight management” or “obesity” under prescription drug benefits and medical benefits
4. Consult your provider: A licensed provider can assess your BMI, document qualifying comorbidities, and initiate the PA process
5. Contact SHIP for free help: Hawaii SHIP at 1-888-875-9229 — free, unbiased Medicare counseling to help you navigate your Humana MAPD plan

Frequently Asked Questions

Does Humana Hawaii cover Ozempic for weight loss?

Ozempic (semaglutide) is FDA-approved for type 2 diabetes management, not specifically for weight loss. Wegovy uses the same active ingredient (semaglutide) but at a higher dose approved for weight management. Under the Medicare GLP-1 Bridge, Wegovy is a covered option at $50/month for eligible MAPD members. Ozempic may be covered under HPS Part D for diabetes management — verify your specific plan. It is not included in the GLP-1 Bridge program (which covers the weight-loss–approved formulations Wegovy, Zepbound, and Foundayo).

Does Humana Hawaii cover Mounjaro for weight loss?

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Zepbound uses the same active ingredient at doses approved for weight management. Under the Medicare GLP-1 Bridge, Zepbound (not Mounjaro) is the covered weight-loss formulation at $50/month for eligible MAPD members. Mounjaro may be covered separately under HPS Part D for diabetes — verify with HPS.

Does Hawaii law require Humana to cover weight loss medication?

Hawaii’s commercial parity law (§ 431M-1) covers mental health and substance use disorder parity — it does not mandate weight loss medication coverage. The Hawaii Prepaid Health Care Act (§ 393) governs commercial employer plans, not Medicare Advantage. Weight loss medication coverage for Humana MAPD members in Hawaii is governed by CMS 42 CFR Part 422 federal regulations and the Medicare GLP-1 Bridge program, not by Hawaii state mandate.

Does EPCS apply to weight loss prescriptions in Hawaii?

No. Hawaii’s EPCS law (HRS § 329-38.5) applies to Schedule II controlled substances only. No weight loss medication is Schedule II. GLP-1s (Wegovy, Zepbound, Foundayo), Contrave, and orlistat are non-scheduled. Phentermine and Qsymia are Schedule IV — outside the scope of HRS § 329-38.5. EPCS requirements do not apply to any current weight loss medication in Hawaii.

Can I get weight loss treatment through telehealth with my Humana Hawaii plan?

Many Humana MAPD plans cover telehealth visits for obesity management, including evaluation, medication management, and follow-up. Check your plan’s Summary of Benefits for telehealth cost-sharing details. Klarity Health’s telehealth providers may be able to provide weight loss treatment and submit PA requests on your behalf — verify your Humana MAPD telehealth benefits before scheduling.

What if Humana denies my weight loss medication PA request?

You have the right to appeal under CMS 42 CFR Part 422. Request a Redetermination from Humana within 60 days. If denied again, request IRE review, then an ALJ hearing (if amount in controversy ≥ $180). Hawaii SHIP (1-888-875-9229) can assist you with appeals at no cost.

Key Contacts

• Humana Member Services: 1-800-448-6262
• Humana Pharmacy Solutions (HPS): 1-800-379-0092
• Humana Provider PA Portal: humana.com/providers (via Availity)
• CMS (Medicare): 1-800-633-4227 | Medicare.gov
• Hawaii SHIP (free Medicare counseling): 1-888-875-9229
• Hawaii Med-QUEST (Medicaid): 1-800-316-8005
• Hawaii Insurance Division (commercial plans only): 1-808-586-2790
• SAMHSA National Helpline: 1-800-662-4357 (free behavioral health support)

Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Insurance coverage may vary significantly by plan, enrollment year, and individual circumstances. Always verify your specific Humana MAPD plan benefits directly with Humana (1-800-448-6262) or HPS (1-800-379-0092) before scheduling treatment or filling a prescription. Coverage decisions are made by Humana and HPS based on your specific plan documents, CMS regulations, and clinical criteria — not by Klarity Health. The Medicare GLP-1 Bridge program parameters described reflect CMS guidance as of July 2026 and may be updated by CMS.

Medicaid/Dual-Eligible Disclaimer: If you are enrolled in both Medicare and Hawaii Medicaid (Med-QUEST), your coverage may differ from what is described above. Contact Hawaii Med-QUEST at 1-800-316-8005 to understand your dual-eligible benefits. This content does not constitute Medicaid coverage guidance.